11/01/2000
David Gration, deputy chairman of fully listed pharmaceutical company Protherics Plc has joined the board of ReGen Therapeutics Plc, a company developing a treatment for Alzheimer’s disease. A fellow of the Royal Pharmaceutical Society, David Gration was previously the executive chairman of Proteus International plc and has held senior positions at The Boots Company, Wyeth Laboratories and Celltech Group. He is also currently chairman of medical company SRS Limited and of Photo Therapeutics Limited, a company developing a treatment for skin cancer.